JAZZ Company Profile
✉ Email this page to a colleague
What is the competitive landscape for JAZZ, and what generic alternatives to JAZZ drugs are available?
JAZZ has seven approved drugs.
There are fifty US patents protecting JAZZ drugs.
There are two hundred and fifty-eight patent family members on JAZZ drugs in thirty-two countries and ninety-three supplementary protection certificates in thirteen countries.
Summary for JAZZ
| International Patents: | 258 |
| US Patents: | 50 |
| Tradenames: | 7 |
| Ingredients: | 7 |
| NDAs: | 7 |
| Patent Litigation for JAZZ: | See patent lawsuits for JAZZ |
| PTAB Cases with JAZZ as patent owner: | See PTAB cases with JAZZ as patent owner |
Drugs and US Patents for JAZZ
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jazz Pharms Res | EPIDIOLEX | cannabidiol | SOLUTION;ORAL | 210365-001 | Sep 28, 2018 | RX | Yes | Yes | 10,966,939 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Jazz | XYWAV | calcium oxybate; magnesium oxybate; potassium oxybate; sodium oxybate | SOLUTION;ORAL | 212690-001 | Jul 21, 2020 | RX | Yes | Yes | 10,195,168 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Jazz | FAZACLO ODT | clozapine | TABLET, ORALLY DISINTEGRATING;ORAL | 021590-002 | Feb 10, 2004 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Jazz Pharms Res | EPIDIOLEX | cannabidiol | SOLUTION;ORAL | 210365-001 | Sep 28, 2018 | RX | Yes | Yes | 11,311,498 | ⤷ Subscribe | ⤷ Subscribe | ||||
| Jazz | XYWAV | calcium oxybate; magnesium oxybate; potassium oxybate; sodium oxybate | SOLUTION;ORAL | 212690-001 | Jul 21, 2020 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for JAZZ
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Jazz | FAZACLO ODT | clozapine | TABLET, ORALLY DISINTEGRATING;ORAL | 021590-001 | Feb 10, 2004 | 6,106,861 | ⤷ Subscribe |
| Jazz | FAZACLO ODT | clozapine | TABLET, ORALLY DISINTEGRATING;ORAL | 021590-005 | Jul 9, 2010 | 6,106,861 | ⤷ Subscribe |
| Jazz | FAZACLO ODT | clozapine | TABLET, ORALLY DISINTEGRATING;ORAL | 021590-002 | Feb 10, 2004 | 6,221,392 | ⤷ Subscribe |
| Jazz | FAZACLO ODT | clozapine | TABLET, ORALLY DISINTEGRATING;ORAL | 021590-004 | May 30, 2007 | 5,178,878 | ⤷ Subscribe |
| Jazz Pharms Res | EPIDIOLEX | cannabidiol | SOLUTION;ORAL | 210365-001 | Sep 28, 2018 | 10,195,159 | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for JAZZ drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Capsules | 100 mg | ➤ Subscribe | 2009-04-20 |
| ➤ Subscribe | Extended-release | 150 mg | ➤ Subscribe | 2009-04-13 |
| ➤ Subscribe | Oral Solution | 500 mg/mL | ➤ Subscribe | 2010-07-08 |
International Patents for JAZZ Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2020510060 | ⤷ Subscribe |
| World Intellectual Property Organization (WIPO) | 2018167303 | ⤷ Subscribe |
| Australia | 2024204928 | ⤷ Subscribe |
| India | 342829 | ⤷ Subscribe |
| Israel | 283086 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for JAZZ Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3141251 | 301099 | Netherlands | ⤷ Subscribe | PRODUCT NAME: A MEDICINAL PRODUCT CONSISTING OF A COMBINATION OF A FIRST DOSE PHARMACEUTICAL COMPOSITION AND A SECOND DOSE PHARMACEUTICAL COMPOSITION, THE FIRST DOSE PHARMACEUTICAL COMPOSITION CONSISTING OF THE ACTIVE INGREDIENTS POLYETHYLENE GLYCOL, SODIUM SULPHATE, SODIUM CHLORIDE AND POTASSIUM CHLORIDE AND THE SECOND DOSE PHARMACEUTICAL COMPOSITION CONSISTING OF THE ACTIVE INGREDIENTS POLYETHYLENE GLYCOL, ASCORBIC ACID, SODIUM ASCORBATE, SODIUM CHLORIDE AND POTASSIUM CHLORIDE; NATIONAL REGISTRATION NO/DATE: RVG 120195 20171114; FIRST REGISTRATION: IS IS/1/17/083/01 20171016 |
| 0268956 | 1999C0030 | Belgium | ⤷ Subscribe | PRODUCT NAME: RABEPRAZOLE SODIUM; NAT. REGISTRATION NO/DATE: 5532 IE 1 F 3 19990201; FIRST REGISTRATION: GB 10555/0010 19980508 |
| 2365988 | LUC00061 | Luxembourg | ⤷ Subscribe | PRODUCT NAME: PATIROMER SORBITEX CALCIUM ET TOUS LES SELS ET DERIVES DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/17/1179 20170721 |
| 2666774 | CA 2020 00037 | Denmark | ⤷ Subscribe | PRODUCT NAME: RELEBACTAM, OPTIONALLY IN THE FORM OF THE MONOHYDRATE, IMIPENEM AND CILASTATIN, OPTIONALLY IN THE FORM OF THE SODIUM SALT; REG. NO/DATE: EU/1/19/1420 20200217 |
| 0480717 | 98C0022 | France | ⤷ Subscribe | PRODUCT NAME: MONTELUKAST SODIUM; REGISTRATION NO/DATE IN FRANCE: NL 23 133 DU 19980320; REGISTRATION NO/DATE AT EEC: 13 651 DU 19970825 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
